Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06047548 · ClinicalTrials.gov registry record · Phase 3
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06047548: Active Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
NCT06047548 is a Phase 3 study of Obesity and Overweight that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 400 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06047548, a Phase 3 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
Primary Outcome
Mean percent maintenance of BW reduction achieved during the 60-Week weight loss period will be measured in participants who have reached a BW plateau.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (20)
Texas
- The University of Texas Health Science Center at Houston - Bellaire
- Velocity Clinical Research, Dallas - Dallas
- Southern Endocrinology Associates - Mesquite
- Pinnacle Clinical Research - San Antonio
- Consano Clinical Research, LLC - Shavano Park
California
- Velocity Clinical Research, Westlake - Los Angeles
- Southern California Dermatology, Inc. - Santa Ana
- Encompass Clinical Research - Spring Valley
Florida
- New Horizon Research Center - Miami
- Oviedo Medical Research - Oviedo
Alabama
- Cahaba Research - Pelham - Pelham
Georgia
- Rophe Adult and Pediatric Medicine/SKYCRNG - Union City
Hawaii
- East-West Medical Research Institute - Honolulu
Idaho
- Rocky Mountain Clinical Research - Idaho Falls
Indiana
- Asha Clinical Research - Munster - Hammond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-09-20 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
What the registry record for NCT06047548 still lists
NCT06047548 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (51% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06047548 names 20 study sites across 13 states, led by Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06047548 about?
NCT06047548 is a clinical study titled "A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities". The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
What is the current status of trial NCT06047548?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2023-09-20. Estimated completion is 2026-05.
What conditions does trial NCT06047548 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT06047548?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06047548?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06047548 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06047548's enrollment target sits among peer trials
400 170th of 1053 higher than 881 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI